These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 25670839)

  • 1. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
    Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
    Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
    Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
    Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.
    Harrison MJ; Lunt M; Verstappen SM; Watson KD; Bansback NJ; Symmons DP
    Health Qual Life Outcomes; 2010 Feb; 8():21. PubMed ID: 20149253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.
    Adams R; Walsh C; Veale D; Bresnihan B; FitzGerald O; Barry M
    Pharmacoeconomics; 2010; 28(6):477-87. PubMed ID: 20465316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of EQ-5D and SF-6D utilities in mental health patients.
    Lamers LM; Bouwmans CA; van Straten A; Donker MC; Hakkaart L
    Health Econ; 2006 Nov; 15(11):1229-36. PubMed ID: 16625671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
    Wong CKH; Lang BHH; Yu HMS; Lam CLK
    Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship Between the Wisconsin Stone Quality of Life (WISQOL) and Preference-Based/Health Utility Measures of Health-Related Quality of Life (HRQoL) in Kidney Stone Patients.
    Polotti C; Tan B; Borglum N; Olweny EO
    Urology; 2020 Jul; 141():33-38. PubMed ID: 32305539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis.
    Barnett C; Bril V; Bayoumi AM
    Eur J Neurol; 2019 Mar; 26(3):452-459. PubMed ID: 30315714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of EQ-5D and SF-6D utilities in Pompe disease.
    Kanters TA; Redekop WK; Kruijshaar ME; van der Ploeg AT; Rutten-van Mölken MP; Hakkaart L
    Qual Life Res; 2015 Apr; 24(4):837-44. PubMed ID: 25342117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responsiveness and minimally important difference of SF-6D and EQ-5D utility scores for the treatment of pelvic organ prolapse.
    Harvie HS; Honeycutt AA; Neuwahl SJ; Barber MD; Richter HE; Visco AG; Sung VW; Shepherd JP; Rogers RG; Jakus-Waldman S; Mazloomdoost D;
    Am J Obstet Gynecol; 2019 Mar; 220(3):265.e1-265.e11. PubMed ID: 30471259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
    Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
    Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
    McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
    J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter?
    Torrance N; Lawson KD; Afolabi E; Bennett MI; Serpell MG; Dunn KM; Smith BH
    Pain; 2014 Oct; 155(10):1996-2004. PubMed ID: 25020004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
    Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
    Cheung PWH; Wong CKH; Cheung JPY
    Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of EuroQol-5D and short form-6D utility scores in multiethnic Asian patients with psoriatic arthritis: a cross-sectional study.
    Leung YY; Png ME; Wee HL; Thumboo J
    J Rheumatol; 2013 Jun; 40(6):859-65. PubMed ID: 23504382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D.
    Kontodimopoulos N; Stamatopoulou E; Brinia A; Talias MA; Ferreira LN
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):667-675. PubMed ID: 30048194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which approach is better in eliciting health state utilities from breast cancer patients? Evidence from mainland China.
    Li S; Wang M; Liu L; Chen G
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12965. PubMed ID: 30499193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.